SANTA BARBARA, Calif. and STOCKHOLM, Sweden, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Palette Life Sciences (“Palette”), a global medical device company dedicated to improving prostate radiation therapy outcomes, announced the signing of an Agreement with Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH) to support the promotion of PYLARIFY^® (piflufolastat F 18) in the United States.
PYLARIFY injection is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence of recurrent and/or metastatic prostate cancer. PYLARIFY was approved by the U.S. Food and Drug Administration in May 2021.
The Agreement provides for Palette’s specialty Urology and Radiation Oncology sales team to fortify Lantheus’ substantial promotional efforts and reach additional U.S. healthcare professionals. The non-exclusive agreement covers an initial one-year term with the opportunity for extension.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Palette’s specialty sales team is expected to begin PYLARIFY promotional efforts in April 2022, educating healthcare practitioners on the availability and benefits of the product. Palette’s specialty sales team was built to support its growing commercial portfolio in the United States.
“This partnership is an important demonstration of Palette’s commitment to providing solutions to physicians and patients across urological disorders, including prostate cancer,” said James Leech, Vice President of Strategy & Corporate Development, Palette Life Sciences. “We are excited to help accelerate Lantheus’ commercial efforts for this novel product and provide promotional support that enables multiple detailing synergies among our sales team within the urology call point. Our commercial team’s strong relationships with many urologists can help drive further awareness of the role of PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer patients in the U.S.”
“We are pleased to collaborate with Palette to expand our own promotional efforts, as well as the promotional efforts of our PET manufacturing partners, with a dedicated urology and radiation oncology sales team,” said Paul Blanchfield, Chief Commercial Officer, Lantheus. “Following the successful launch and rapid adoption of PYLARIFY, we are doubling down on our commitment to improve patient outcomes by increasing our ability to reach even more physicians who can use PYLARIFY to help find, fight and follow prostate cancer.”
